Comparison of fentanyl and droperidol mixture (neuroleptanalgesia II) with morphine on clinical outcomes in unstable angina patients

Cardiovascular Drugs and Therapy

Volumn 14, Issue 3, 2000, Pages 259-269

  Burduk, Piotr ^c   Guzik, Przemyslaw ^a   Piechocka, Maria ^c   Bronisz, Marek ^c   Rozek, Andrzej ^c   Jazdon, Maciej ^c   Jordan, Michael R ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Acute myocardial infarction; Analgesics; Droperidol; Fentanyl; Morphine; Mortality; Neuroleptanalgesia; Recurrent ischemia; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; DROPERIDOL; FENTANYL; GLYCERYL TRINITRATE; HEPARIN; MORPHINE; POLOPIRYNA S;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENDER; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; NEUROLEPTANALGESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VOMITING;

ANALGESICS, OPIOID; ANGINA, UNSTABLE; CHROMATOGRAPHY, GAS; DOPAMINE ANTAGONISTS; DROPERIDOL; DRUG THERAPY, COMBINATION; FEMALE; FENTANYL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEUROLEPTANALGESIA; ODDS RATIO; PAIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033922793     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007826506825     Document Type: Article

References (76)

1. 1. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428.
2. 2. Borzak S, Cannon CP, Kraft PL, et al. for TIMI 7 Investigators. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol 1998;81:678-681.
3. 3. Braunwald E, Jones RH, Mark DB, et al. Diagnosis and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994;90:613-622.
4. 4. Lown B, Vassaux C, Hood WB, Fakhro AM, Kaplinsky E, Roberge G. Unresolved problems in coronary care. Am J Cardiol 1967;20:494-508.
5. 5. Pasternak RC, Braunwald E. Acute myocardial infarction. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine, 12th ed. New York: McGraw Hill, 1991:953-964.
6. 6. Brown BR, Blitt CD, Vaughan RW. Pharmacology of anesthetics and adjuvants. In: Brown BR, Blitt CD, Vaughan RW, eds. Clinical Anesthesiology. St. Louis, MO: C.V. Mosby, 1985:50-119.
7. 7. Luczak J, Brodzińska K, Skubiszyńska A, Szmydt W. Neuroleptanalgesia II in recent myocardial infarction. Pol Med J 1969;8:1297-1302.
8. 8. Kaniak J, Suchnicka R, Zagrobelny Z. [Myocardial infarction treated by neuroleptoanalgesia type II (NLA II)]. Pol Tyg Lek 1969;24:592-595.
9. 9. Siler Z, Tovarys A, Micík L. [Neuroleptoanalgesia in the treatment of acute myocardial infarct]. Vnitr Lek 1973;19:468-477.
10. 10. Tevelenok IuA. [Use of drugs for neuroleptoanalgesia in the acute period of a myocardial infarct.] Kardiologiia 1971;11:55-59.
11. 11. Pall H, Kleinberger G, Kotzaurek R, et al. [Analgesia with neuroleptic drugs in recent myocardial infarction]. Wien Klin Wochenschr 1973;85:804-806.
12. 12. Magometschnigg D, Hörtnagl H, Gassner A, et al. Neuroleptanalgesia in acute myocardial infarction: Effects of hemodynamic parameters and plasma catecholamines. Clin Cardiol 1981;4:238-242.
13. 13. Riberio LGT, Yasuda T, Lowenstein E, Braunwald E, Maroko PR. Comparative effects of anatomic infarct size of verapamil, ibuprofen and morphine-prometazine-chlorpromazine combination (abstr). Am J Cardiol 1979;43:396.
14. 14. Schultz JEJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (δ)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997;29:2187-2195.
15. 15. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996;78:1100-1104.
16. 16. Miki T, Downey J. Opioid receptors participate in ischemic preconditioning in rabbits. J Mol Cell Cardiol 1996;28:A187.
17. 17. Markiewicz W, Finberg JP, Lichtig C. Morphine increases myocardial infarction size in rats. Anesth Analg 1982;61:843-846.
18. 18. Dlużniewski M, Bednarz B, Kloś J, Budaj A, Ceremużyński L. [The influence of the "lytic mixture" (morphine-chlorpromazine-prometazine) administration on catecholamine excretion]. Kard Pol 1987;30:137-143.
19. 19. Ceremużyński L, Dlużniewski M, Nartowicz E, et al. Effects of morphine-chlorpromazine-prometazine treatment in patients with acute myocardial infarction - preliminary results of a randomized study (abstr). Circulation 1983;68(Suppl. III):370.
20. 20. Ceremużyński L, Dlużniewski M, Krzemińska-Pakula M, et al. [Lytic coctail (morphine, chlorpromazine and prometazine) in treatment of acute myocardial infarction]. Kard Pol 1987;30:71-79.
21. 21. Braunwald E. Unstable angina. A classification. Circulation 1989;80:410-414.
22. 22. Kaplan E, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. 23. Jaeschke R, Guyatt G, Shannon H, Walter S, Cook D, Heddle N. Assessing the effects of the treatment: Measures of association. CMAJ 1995;152:351-357.
24. 24. Guyatt G, Walter S, Shannon H, Cook D, Jaeschke R, Heddle N. Correlation and regression. CMAJ 1995;152:497-504.
25. 25. Thamer V, Deussen A, Schipke JD, Tolle T, Heusch G. Pain and myocardial ischemia: The role of sympathetic activation. Basic Res Cardiol 1990;85(Suppl. 1):253-266.
26. 26. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart Disease - A Textbook of Cardiovascular Medicine, 5th ed. London: WBSaunders, 1997;85:1184-1288.
27. 27. Brunelli C, Spallarossa P, Rossettin P, Caponnetto S. Recognition and treatment of unstable angina. Drugs 1996;52:196-208.
28. 28. Kim YI, Williams JF, Jr. Large dose sublingual nitroglycerin in acute myocardial infarction: Relief of chest pain and reduction of Q wave evolution. Am J Cardiol 1982;49:842-848.
29. 29. Shotan A, Brill Z, Matetzky S, et al. Pain scoring - a method for assessing therapy comparison of the response to acute sublingual administration of an isosorbide dinitrate tablet, isosorbide dinitrate and nitroglycerin spray in unstable angina. Cardiology 1998;89:163-169.
30. 30. Dzizinsky AA, Tumak VN, Bidagaev VB. [The use of morphine-prolonged epidural analgesia for pain syndrome relief in acute period of myocardial infarct]. Anesteziol Reanimatol 1991;5:43-45.
31. 31. Wojtasik W. [A comparative evaluation of effect of neuroleptoanalgesia II and morphine on clinical changes in recent myocardial infarction]. Przegl Lek 1975;32:702-705.
32. 32. Camm AJ, Fei L. Clinical significance of heart rate variability. In: Moss AJ, Stern S, eds. Noninvasive Electrocardiology. Clinical Aspects of Holter Monitoring. London: WB Saunders, 1996:225-248.
33. 33. Kleiger RE, Miller JP, Bigger JT Jr., Moss AJ, and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;89:256-262.
34. 34. La Rovere MT, Bigger JT Jr., Marcus FI, Mortara A, Schwartz PJ, for the ATRAMI (Autonomie Tone and Reflex After Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
35. 35. Ohsumi H, Sakamoto M, Yamazaki T, Okumura F. Effects of fentanyl on carotid sinus baroreflex control of circulation in rabbits. Am J Physiol 1989;256:R625-R631.
36. 36. Saini V, Carr DB, Hagestad EL, Lown B, Verrier RL. Antifibrillatory action of the narcotic agonist fentanyl. Am Heart J 1988;115:598-605.
37. 37. Napier LD, Stanfill A, Yoshishige DA, Jackson KE, Barron BA, Caffrey JL. Autonomic control of heart rate in dogs treated chronically with morphine. Am J Physiol 1998;275:H2199-H2210.
38. 38. Zickmann B, Hofmann HC, Pottkamper C, Knothe C, Boldt J, Hempelmann G. Changes in heart rate variability during induction of anesthesia with fentanyl and midazolam. J Cardiothorac Vasc Anesth 1996;10:609-613.
39. 39. Michaloudis D, Kochiadakis G, Georgopoulou G, et al. The influence of premedication on heart rate variability. Anaesthesia 1998;53:446-453.
40. 40. Storella RJ, Kandell RB, Morrow JC, Ackerman TS, Polansky M, Zietz S. Nonlinear measures of heart rate variability after fentanyl-based induction of anesthesia. Anesth Analg 1995;81:1292-1294.
41. 41. Taneyama C, Goto H, Kohno N, Benson KT, Sasao J, Arakawa K. Effects of fentanyl, diazepam, and the combination of both on arterial baroreflex and sympathetic nerve activity in intact and baro-denervated dogs. Anesth Analg 1993;77:44-48.
42. 42. Balagny D, Gauzit R, Marty J, Couderc E, Levron JC, Desmonts JM. Effects of droperidol on sympathetic activity and baroreflex control of heart rate in humans. Anesthesiology 1987;67:473-476.
43. 43. Addicks K, Hirche H, McDonald FM, Polwin W. Effects of morphine on catecholamine release and arrhythmias evoked by myocardial ischaemia in rats. Br J Pharmacol 1987;90:247-254.
44. 44. Laubie M, Schmidt H, Vincent M, Remona C. Central cardiovascular effect of morphine-omimetic peptides in dogs. Eur J Pharmac 1977;46:67-71.
45. 45. Jorm CM, Stamford JA. Action of morphine on noradrenaline efflux in the rat locus coeruleus are mediated via both opioid and α2 adrenoreceptor mechanisms. Br J Anaesth 1995;74:73-78.
46. 46. Sumikawa K, Hirano H, Amakata Y, Kashimoto T, Wada A, Izumi F. Mechanism of the effect of droperidol to induce catecholamine efflux from the adrenal medulla. Anesthesiology 1985;62:17-22.
47. 47. Montiel C, Artalejo AR, Bermejo PM, Sanchez-Garcia P. A dopaminergic receptor in adrenal medulla as a possible site of action for the droperidol-evoked hypertensive response. Anesthesiology 1986;65:474-479.
48. 48. Wheatley AM, Thandroyen FT, Opie LH. Catecholamine-induced myocardial cell damage: Catecholamines or adrenochrome. J Moll Cell Cardiol 1985;17:349-359.
49. 49. Opie LH. The mechanism of myocyte death in ischaemia. Eur Heart J 1993;14(Suppl. G):31-33.
50. 50. Tsuchida A, Miura T, Tanno M, Nozawa Y, Kita H, Shimamoto K. Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart. Cardiovasc Drugs Ther 1998;12:365-373.
51. 51. Schultz JE, Hsu AK, Nagase H, Gross GJ. TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol 1998;274:H909-H914.
52. 52. Fryer RM, Hsu AK, Eells JT, Nagase H, Gross GJ. Opioid-induced second window of cardioprotection: Potential role of mitochondrial KATP channels. Circ Res 1999;84:846-851.
53. 53. Kamei J, Kawashima N, Narita M, Suzuki T, Misawa M, Kasuya Y. Reduction in ATP sensitive potassium channel-mediated antinociception in diabetic mice. Psychopharmacol Berl 1994;113:318-321.
54. 54. Yamanoue T, Brum JM, Estafanous FG, Ferrario CM, Khairallah PA. Effects of opioids on vasoresponsiveness of porcine coronary artery. Anesth Analg 1992;74:889-896.
55. 55. Blaise G, Witzeling TM, Sill JC, Vinay P, Vanhoutte PM. Fentanyl is devoid of major effects on coronary vasoreactivity and myocardial metabolism in experimental animals. Anesthesiology 1990;72:535-541.
56. 56. Toda N, Hatano Y. Alpha-adrenergic blocking action of fentanyl on the isolated aorta of the rabbit. Anesthesiology 1977;46:411-416.
57. 57. Crystal GJ, Gurevicius J, Salem MR, Zhou X. Role of adenosine triphosphate-sensitive potassium channels in coronary vasodilation by halothane, isoflurane, and enflurane. Anesthesiology 1997;86:448-458.
58. 58. Sumeray MS, Yellon DM. Myocardial preconditioning. What have we learned? Eur Heart J 1997;18(Suppl. A):A8-A14.
59. 59. Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G, Sumeray MS. Ischemic preconditioning: Present position and future direction. Cardiovasc Res 1998;37:21-33.
60. 60. Stewart RA, Simmonds MB, Williams MJ. Time course of "warm-up" in stable angina. Am J Cardiol 1995;76:70-73.
61. 61. Iwasaka T, Nakamura S, Karakawa M, Sugiura T, Inada M. Cardioprotective effect of unstable angina prior to acute myocardial infarction. Chest 1994;105:57-61.
62. 62. Xenopoulos NP, Leesar M, Bolli R. Morphine mimics ischemic preconditioning in human myocardium during PTCA (abstr). J Am Coll Cardiol 1998;31(Suppl. A):65.
63. 63. Tomai F, Crea F, Gaspardone A, et al. Role of opioids in ischaemic preconditioning in man (abstr). Eur Heart J 1998;19(Suppl.):26.
64. 64. Burduk P, Drewa G, Piechocka M, et al. Antioxidative effects of morphine in recent myocardial infarction (abstr). Cardiovasc Drugs Ther 1997;11(Suppl. 2):67.
65. 65. Chan SY, Huo QL, Huang JB, Chen ZL, Shi XH, Liao XL. Morphine inhibited respiratory burst of neutrophils and scavenged oxygen free radicals. Acta Pharmacol Sinica 1995;16:445-448.
66. 66. Wang TL, Chang H, Hung CR, Tseng YZ. Attenuation of neutrophil and endothelial activation by intravenous morphine in patients with acute myocardial infarction. Am J Cardiol 1997;80:1532-1535.
67. 67. Bian TH, Wang XF, Li XY. Effects of morphine on interleukin-1 and tumor necrosis factor production from mouse peritoneal macrophages in vitro. Acta Pharmacol Sinica 1995;16:449-451.
68. 68. Pruett SB, Han YC, Fuchs BA. Morphine suppresses primary humoral responses by a predominantly indirect mechanism. J Pharmacol Exp Ther 1992;262:923-928.
69. 69. Kanda T, Hirao Y, Oshima S, et al. Intereleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996;77:304-307.
70. 70. Dubois-Rande JL, Artigou JY, Darmon JY, et al. Oxidative stress in patients with unstable angina. Eur Heart J 1994;15:179-183.
71. 71. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778.
72. 72. Bilfinger TV, Fimiani C, Stefano GB. Morphine's immunoregulatory actions are not shared by fentanyl. Int J Cardiol 1998;64(Suppl. I):S61-S66.
73. 73. Burduk P, Drewa G, Guzik P, et al. The influence of neuroleptanalgesia or morphine on clinical outcomes in patients with acute myocardial infarction (abstr). Eur Heart J 1998;19(Suppl.):283.
74. 74. Burduk P, Drewa G, Guzik P, et al. Clinical outcomes in unstable angina patients treated with neuroleptanalgesia or morphine (abstr). Eur Heart J 1998;19(Suppl.):283.
75. 75. Budaj A. Miejsce poszczególnych interwencji terapeutycznych w leczeniu zawalu serca. In: Ceremużyński L, ed. Zawal Serca. Mechanizmy Choroby, Wspólczesne leczenie. Warszawa: Agencja Wydawnicza Mako, 1994: 23-63.
76. 76. Sadowski Z, Budaj A, Dlużniewski M, et al. Zawal serca. In: Polskie Towarzystwo Kardiologiczne. Standardy Postepowania w Chorobach Ukladu Krażenia. Kard Pol 1997;46(Suppl. 1):19-32.